Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases

Azam Hosseinzadeh, Nazila Alinaghian, Mohammad Sheibani, Farnoosh Seirafianpour, Ali Jamshidi Naeini, Saeed Mehrzadi
Life sciences · 2024 · vol. 344 , pp. 122557 · doi:10.1016/j.lfs.2024.122557 · PMID:38479596 · W4392653719
article OA: closed CC0 ⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This review synthesizes current evidence on melatonin's protective and therapeutic effects in various gynecological diseases, including endometriosis, polycystic ovary syndrome, and gynecological cancers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Melatonin Melatonin Melatonin Melatonin Melatonin Melatonin Melatonin Melatonin Melatonin Melatonin Polycystic Ovary Syndrome Polycystic Ovary Syndrome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-06-01T00:32:53.791668+00:00
License: CC0 · commercial use OK